RESEARCH
- Beijing
- Anhui
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd.
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. (Zhifei Lvzhu for short), a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., is a national high-tech enterprise integrating vaccine research, development, production and sales. Zhifei Lvzhu is mainly engaged in the research, development, production and sales of vaccines, based on its registered capital of RMB1.332 billion and a factory area of 55,106 square meters. Based in Yizhuang Estate of Zhongguancun Science Park, Beijing, Zhifei Lvzhuis is building a new vaccine industrialization production site, aiming at developing and producing new vaccine agents on a larger scale. The company is committed to the research, development and production of new vaccines for human use, covering mainly three research parts, namely 1) bacterial vaccines: the commercially available Group ACYW135 Meningococcal Polysaccharide Vaccine (product name: Menwayc®), Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine (product name: Mening A Con®), Haemophilus Influenzae Type b Vaccine, and Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine; the upcoming Pneumococcal 15-valent Conjugate Vaccine, Group ACYW135 Meningococcal Polysaccharide Vaccine, Pneumococcal 23-Valent Polysaccharide Vaccine, Dysentery Conjugate Vaccine of S.flexneri and S.Sonnei, and Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine; 2) genetic engineering based vaccines: the upcoming Recombinant Group A Meningococcal Meningitis Vaccine, etc.; and 3) viral vaccines: the upcoming hand-foot-mouth disease vaccines, etc.
After 17 years of innovation and development, Zhifei Lvzhu has successively been conferred Beijing “G20 Project” Innovation Leading Enterprise, Beijing Enterprise with Honesty and Credit, Beijing Patent Pilot Unit, Zhongguancun “Ten-Hundred-Thousand-Project” Enterprise, Zhongguancun “Gazelle Enterprise” and Advanced Unit of Science and Technology Innovation in Beijing Economic and Technological Development Zone.Zhifei Lvzhu adheres to the company tenet of “Prioritize social benefits over corporate profits” and the development idea of “Be people-oriented, and keep on improving”, takes vaccines for human use as the main research focus, insists on independent research and development, and actively introduces international leading technologies to develop and produce various vaccine products and biotechnology based drugs demanded by the market for disease prevention, control and treatment.
-
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei Longcom for short), a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd., is a national high-tech enterprise integrating biological product research, development, production and sales. Zhifei Longcom is mainly engaged in the research, development, production and sales of biological products (immunologic agents, vaccines and GE products), based on its registered capital of RMB765 million and a factory area of 216,282 square meters. The company has acquired 415.7 mu of land in the National Health and Medical Big Data Central Industrial Park within Hefei National High-tech Industry Development Zone to build a biopharmaceutical industrial park project. The company is committed to the research, development and production of new vaccines for human use, covering mainly two research parts, namely 1) tuberculosis related products: the commercially available Mycobacterium Vaccae for Injection (product name: Vaccae®) and Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (product name: Ekear®), and the upcoming Mycobacterium Vaccae Vaccine for TB Infected Population Use; and 2) viral vaccines: the upcoming influenza vaccine, rabies vaccines, norovirus vaccine, recombinant subunit 2019-nCoV vaccine, etc.
In recent years, Zhifei Longcom has received various honors and titles, such as “Certificate of High & New Technological Enterprise”, “National Key New Product Certificate”, “Innovative Pilot Enterprise of Anhui Province”, “New-type Human Vaccine Engineering Technology Research Center of Anhui Province”, “Hefei Municipal Enterprise Technical Center”, “Informatization and Industrialization Integration Model Enterprise of Hefei City”. The company has also undertaken five national major special programs for infectious disease prevention and control, and three national major special program for new drugs innovation.Zhifei Longcom adheres to the company tenet of “Prioritize social benefits over corporate profits” and the development idea of “Focusing on R&D, promoting production, guaranteeing quality and accelerating growth”, aiming to build a world-class biopharmaceutical R&D and production platform, create national brands, provide safe, effective and quality controllable biological products for the society. Taking “Realize Zhifei Dream, Bio Dream, Health Dream and Chinese Dream” as the objective, Zhifei Longcom is committed to serving the national health and making contributions to the national health strategy
